[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"srs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:srs":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,57,82,114,140],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":42,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100431578","phase-2-stereotactic-brain-directed-radiation-with-or-without-aguix-gadolinium-based-nanoparticles-in-brain-metastases-100431578",false,"NCT04899908","Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases","A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone","Inclusion Criteria:\n\n* Participants must have a biopsy proven solid malignancy and at least one intracranial measurable lesion spanning ≥5mm in maximal unidimensional size and radiographically consistent with or pathologically proven to be a brain metastasis AND meet one of the following additional criteria regarding the primary site or nature of the intracranial disease:\n\n  * Melanoma with intracranial growth consistent with tumor progression despite immunotherapy\n  * Gastrointestinal primary\n  * HER2 positive breast cancer (subtype assessed using most representative tissue available in opinion of enrolling clinician and\u002For study PI)\n  * Cystic metastases\n  * Metastases ≥2cm in maximal unidimensional size\n  * Locally recurrent metastases after prior stereotactic radiation\n  * Locally recurrent metastases after prior whole brain radiation \\*Patients with metastases from melanoma, GI primaries, or HER2+ breast cancer, as well as those with cystic metastases or metastases ≥2cm in maximal unidimensional size, who have local recurrences after prior brain-directed radiation can only be treated in the strata permitting prior radiation (last two strata above)\n* Age ≥18 years at diagnosis of brain metastases\n* Estimated glomerular filtration rate of ≥ 60 mL\u002Fmin\u002F1.73m2\n* Karnofsky performance status of at least 70 (i.e. at minimum, \"cares for self\" but \"unable to carry on normal activity or do active work\")\n* Estimated survival based on extracranial disease of at least 3 months in the opinion of the enrolling clinician and\u002For study PI\n* Ability to understand and the willingness to sign a written informed consent document\n* The effects of AGuIX on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of the therapeutic component of study participation\n\nExclusion Criteria:\n\n* Participants who cannot undergo a brain MRI\n* Participants who cannot receive gadolinium\n* Participants with widespread, definitive leptomeningeal disease\n* Patients requiring radiation to either \\>10 targets (if naïve to whole brain radiation) or \\>20 targets (if whole brain radiation has been given previously) per the discretion of the treating clinician and\u002For study PI\n* Pregnant women are excluded from this study because of the potential deleterious effects of gadolinium on the developing fetus. Because there is an unknown but potential risk for adverse events in nursing infants, women who are breastfeeding are not eligible for this study\n* In cohorts who have received prior brain-directed radiation, patients are not eligible for this study if they have active (at the time of protocol screening) brain metastases that require radiation that are in or within 1.0cm of the brainstem, eyes, optic nerves, or optic chiasm if the juxtaposed organ at risk (i.e. brainstem, eyes, optic nerves, or optic chiasm) has previously received either \\>6.0 Gy in a single fraction or, if prior radiation was fractionated, a cumulative dose in 2.0 Gy equivalents, using an alpha\u002Fbeta ratio of 2, of \\>40.0 Gy. In addition, all patients who have had prior brain-directed radiation, regardless of technique\u002Fdose\u002Ffractionation, are not eligible for the study until written approval is provided by the study\u002Fsite PI","ALL","18 Years",{"count":19,"type":20},134,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more difficult to control with stereotactic radiation alone.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41],"Brain Cancer","Brain Metastases","Melanoma","Lung Cancer","Breast Cancer","HER2-positive Breast Cancer","Colorectal Cancer","Gastrointestinal Cancer","SRS","SRT","Whole Brain Radiation","Stereotactic Radiation","AGuIX","Nanoparticle","Cystic","Brain Tumor",[26,27,28,29,30,31,32,33,34,35,43,37,38,39,40,41],"Whole brain radiation","RECRUITING","2026-06-16",{"date":47,"type":48},"2026-06-17","ACTUAL",{"date":50,"type":48},"2021-09-15",{"date":52,"type":20},"2029-05",{"name":54,"class":55},"Brigham and Women's Hospital","OTHER",2,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":21,"phases":67,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100605417","phase-2-combined-gamma-knifelinac-radiosurgery-for-large-brain-tumors--metastases-100605417","NCT07162246","Combined Gamma Knife\u002FLinac Radiosurgery for Large Brain Tumors \u002F Metastases","Combined Gamma Knife\u002FLinac Hypofractionated Stereotactic Radiosurgery for Large Intracranial VolumEs (GK-LIVE): A Prospective Phase II Single-Arm Trial","GK-LIVE","Inclusion Criteria:\n\n* Presence of up to two large intracranial lesions\n* Up to 10 (previously untreated, or progressing after previous treatment) brain metastases at the time of enrollment on the diagnostic MRI (which includes the ILLs) to be treated with SRS\u002FHSRS\n* Age =\\> 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Expected survival \\>3 months\n* Patients that are deemed suitable for both GK and Linac based treatment\n* Patients that are able to hold systemic cancer chemotherapy\u002Fimmunotherapy at least 2 days prior and following an SRS fraction\n\nExclusion Criteria:\n\n* Prior SRS to the ILLs\n* Prior WBRT, or plan for concurrent WBRT with the protocol treatment\n* Presence or history of any leptomeningeal\u002Fpachymeningeal disease\n* Metastatic disease within the ventricles of the brain or corpus callosum\n* Small cell, hematopoietic or germ cell primaries\n* Patient with absolutely contraindications for MRI\n* Severe symptoms that preclude MRI or treatment using standard procedures for Linac or GK\n* Pregnant or lactating patient\n* Inability or unwillingness to undergo informed consent or post-treatment follow-up",{"count":66,"type":20},60,[23],"When cancer spreads to the brain, doctors often use a precise type of radiation therapy called stereotactic radiosurgery (SRS) to treat these tumors. This treatment can effectively control brain tumors while helping protect healthy brain tissue. However, when brain tumors or the areas where tumors were surgically removed are larger, treatment outcomes in terms of side effects and tumour control can become worse. Specifically, standard SRS on larger areas can have lower tumour control and higher risk of side effects, particularly a condition called radiation necrosis, which can cause swelling and damage in nearby healthy brain tissue.\n\nCurrently at Sunnybrook, large brain tumors are typically treated with SRS spread over 5 daily treatments using a machine called a linear accelerator. While this approach works well for many patients, it may be possible to improve results by combining two different types of radiation therapy machines - the linear accelerator and another specialized machine called the Gamma Knife.\n\nIn this study, the investigators want to test a new treatment approach where patients first receive 4 daily treatments using the linear accelerator, followed by a 1-2 week break, and then a final treatment using the Gamma Knife. The break between treatments allows the study doctors to take new scans and precisely target any remaining tumor, which may shrink during the break, thereby potentially reducing the amount of healthy brain tissue exposed to radiation. The Gamma Knife is also particularly good at delivering very precise radiation while sparing nearby healthy tissue. Lastly, there may be unique biological mechanisms between the two technologies that could be taken advantage of, by combining the technologies in the participant's treatment plan, to improve cancer control.\n\nThe investigators believe this combined approach might help achieve better tumor control while reducing the risk of side effects compared to using just the linear accelerator. This study will help the investigators understand if this new treatment strategy is safe and effective for patients with large brain tumors or surgical cavities, and whether it leads to better outcomes than the current treatment approach.",[70,71,34],"Brain (Nervous System) Cancers","Brain Metastasases","2025-09-05",{"date":74,"type":48},"2025-09-09",{"date":76,"type":48},"2025-07-14",{"date":78,"type":20},"2030-06",{"name":80,"class":55},"Sunnybrook Health Sciences Centre",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":21,"phases":93,"briefSummary":95,"conditions":96,"keywords":101,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":81},"100551270","phase-3-srssrthypo-rt-versus-ha-wbrt-for-no-more-than-10-brain-metastases-in-sclc-100551270","NCT06457906","SRS\u002FSRT\u002FHypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC","SRS\u002FSRT\u002FHypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in Patients With Small-Cell Lung Cancer: A Prospective, Randomized, Multicenter Phase III Trial (SHARP Trial)","SHARP","Inclusion Criteria:\n\nInvestigators should consider these factors when selecting patients for this trial. Investigators also should consider all other relevant factors (medical and non-medical), as well as the risks and benefits of the study therapy, when deciding if a patient is an appropriate candidate for this trial.\n\n1. Adult patients (18-80 years of age) with Eastern Cooperative Oncology Group performance status 0-2 or Karnofsky performance score ≥ 70, expected life time more than 6 months;\n2. Pathologically (histologically or cytologically) proven diagnosis of small cell lung cancer within 5 years of registration. If the original histologic proof of malignancy is greater than 5 years, then pathological (i.e., more recent) confirmation is required (e.g., from a systemic or brain metastasis). Patients with de novo or recurrent small cell lung cancer are permitted;\n3. No more than 10 metastatic brain lesions with ≤5 cm in largest diameter and ≤150 ml in treated volume, confirmed by a high-resolution (thickness ≤2mm) , 3-dimensional T1-weighted postgadolinium magnetic resonance imaging (MRI) brain scan within 2 weeks of study initiation. All brain metastases must be outside a 5-mm margin around either hippocampus or optic pathways.\n4. Not all metastatic brain lesions are recommended or suitable for surgical resection after multidisciplinary team discussion. If part of metastatic brain lesions are resected, the patient is permitted for enrollment evaluation at least two weeks after resection; 5 Patients must have the psychological ability and general health that permits completion of the study requirements, all assessment (HVLT-R, MoCA, EORTC QLQ-C30) and required follow up (at least 6 months);\n\n6\\. At least one measurable BM according to the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) criteria; 7. Women of childbearing potential and men who are sexually active should be willing and able to use medically acceptable forms of contraception during treatment on this study and for up to 180 days after completion of all treatment to prevent pregnancy or fathering a child; 8. Written informed consent (must be available before enrolment in the trial).\n\nExclusion Criteria:\n\n1. Clinical or radiologic evidence of new, untreated, and\u002For progressive brain metastases prior to registration;\n2. Previous radiotherapy of the brain;\n3. Patients can not tolerate immobilization or are with MRI contraindication (i.e., cardiac pacemaker, implanted defibrillator, certain cardiac valve replacements, certain metal implants);\n4. Radiographic evidence of hydrocephalus or other architectural distortion of the ventricular system, leptomeningeal metastases, increased intracranial pressure requiring immediate depression surgery.\n5. Patients who have not yet recovered from acute high-grade (≥Grade 3) toxicities of prior therapies according Common Terminology Criteria for Adverse EventsVersion5.0 (CTC 5.0);\n6. Presence of other serious illnesses such as acute myocardial infarction, severe arrhythmia, or psychiatric disorders within the past 6 months;\n7. Known carcinoma \\\u003C 5 years ago (excluding carcinoma in situ of the cervix, basal cell carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment interfering with study therapy;\n8. Pregnant or lactating women;\n9. Participation in another clinical study or observation period of competing trials, respectively;","80 Years",{"count":92,"type":20},340,[94],"PHASE3","This phase III trial compares the effect of stereotactic radiosurgery and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain.",[97,27,34,98,99,100],"Small-cell Lung Cancer","Stereotactic Radiotherapy","Whole Brain Radiotherpay","Hippocampal-avoidance",[97,27,34,102,103,104,100],"Stereotactic radiotherapy","Whole brain radiotherpay","Hypofractionaed radiotherapy","2025-07-12",{"date":107,"type":48},"2025-07-16",{"date":109,"type":48},"2023-09-01",{"date":111,"type":20},"2028-02-28",{"name":113,"class":55},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":90,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":125,"conditions":126,"keywords":128,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":4},"100581568","efficacy-of-the-rayerknife-x-stereotactic-radiotherapy-system-in-the-treatment-of-brain-metastases-100581568","NCT06852001","Efficacy of the RayerKnife X Stereotactic Radiotherapy System in the Treatment of Brain Metastases","A Prospective, Multi-center, Single-Arm Study on the Efficacy of the RayerKnife X Stereotactic Radiotherapy System in the Treatment of Brain Metastases","Inclusion Criteria:\n\n1. Age between 18 and 80 years (inclusive), regardless of gender.\n2. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n3. Diagnosis of brain metastasis confirmed by histopathological examination and\u002For imaging, and deemed suitable for stereotactic radiotherapy according to the investigator's judgment.\n4. Tumor diameter of brain metastasis ≤ 4 cm, with ≤ 10 metastatic lesions.\n5. At least one measurable tumor lesion as defined by the RECIST 1.1 criteria for assessment of treatment efficacy.\n6. Ability to understand the study objectives, voluntarily consent to participate, and sign a written informed consent; willingness to undergo all necessary examinations and follow-up assessments.\n\nExclusion Criteria:\n\n1. Expected survival time \\\u003C 6 months.\n2. Patients requiring surgical treatment or other local therapies for the target lesions during radiotherapy.\n3. Patients who have received other local treatments (including radiofrequency ablation, cryoablation, particle therapy, etc.) within 30 days prior to screening, or those who have received systemic therapy (chemotherapy, endocrine therapy, immunotherapy) within 14 days or less than five half-lives of a drug prior to screening (whichever is longer).\n4. Patients who have previously received radiotherapy at the same site or for the same lesion.\n5. Patients with extensive metastasis, severe cachexia, or clear signs of malignant cachexia.\n6. Patients deemed by the investigator to be unable to tolerate radiotherapy.\n7. Patients with psychiatric disorders or who are unable to accurately describe their condition or cooperate with required examinations.\n8. Patients with systemic active infections or infections of the pericardium or lungs.\n9. Patients with severe liver or renal dysfunction, or those with significant concurrent diseases in other systems.\n10. Patients with septic hemorrhagic shock.\n11. Patients with esophageal cancer at risk for deep ulceration or perforation, or those with large pleural effusion in lung cancer or significant ascites in abdominal tumors.\n12. Pregnant or breastfeeding women, or women planning to become pregnant during the study period or unwilling to take appropriate contraceptive measures (acceptable methods include hormonal therapies (oral, implant, etc.), intrauterine devices, barrier methods (spermicide + condom), spermicide + diaphragm\u002Fcervical cap, abstinence, etc.).\n13. Low blood counts (leukocyte count \\\u003C 2.0 × 10⁹\u002FL, platelet count \\\u003C 50 × 10⁹\u002FL, or hemoglobin \\\u003C 80 g\u002FL), or abnormal laboratory values exceeding the normal range with clinical significance.\n14. Participation in any drug or medical device clinical trial within 30 days prior to screening or currently enrolled in another clinical study.\n15. Any other condition deemed by the investigator to be inappropriate for participation in this study.",{"count":122,"type":20},34,[124],"NA","The goal of this clinical trial is to evaluate the efficacy of stereotactic radiotherapy in the treatment of brain metastases. The main question it aims to answer is: Did stereotactic radiotherapy improve LC rate in the treatment of brain metastases? Participants will be recorded for local control rates during follow-up.",[127,34],"Brain Metastasis",[129],"Radiotherapy","NOT_YET_RECRUITING","2025-02-24",{"date":133,"type":48},"2025-02-28",{"date":135,"type":20},"2025-03-01",{"date":137,"type":20},"2026-03-01",{"name":139,"class":55},"Tianjin Medical University Cancer Institute and Hospital",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":150,"phases":4,"briefSummary":151,"conditions":152,"keywords":156,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":81},"100355985","quality-of-life-hrqol-of-ais-patients-who-require-bracing-or-surgery-using-srs-22-questionnaire-100355985","NCT03915106","Quality of Life (HRQoL) of AIS Patients Who Require Bracing or Surgery Using SRS-22 Questionnaire","Evaluation of Health-related Quality of Life (HRQoL) of Adolescent Idiopathic Scoliosis (AIS) Patients Who Require Bracing or Surgery Using SRS-22 Questionnaire","QolAISSRS22","Inclusion Criteria:\n\n* AIS patients who attend the scoliosis clinic at specialized outpatient clinic in Prince of Wales hospital and require wearing brace, or patients who suffer from severe scoliosis and require surgery on their first clinic visit\n* Can read and understand either English or Chinese\n\nExclusion Criteria:\n\n* To observe (i.e. not require to wear brace) after clinic visit\n* Cannot read or understand either English or Chinese",{"count":149,"type":20},2000,"OBSERVATIONAL","Adolescent Idiopathic Scoliosis (AIS) is an unexpected curvature of spine at teenage. AIS causes mainly unpleasant appearance, and sometime comes with pain and difficult to locate or move around. When the spinal curve, or \"Cobb angle\", increases with time, the investigators call it severe condition when the Cobb angle is 60 degrees or above. The severe suffering patients need to be operated to correct their spinal curve by using metallic rods and metallic screws (implants) to fix the spine. In order to avoid this surgery, the investigators use \"brace\", a hard fitting case, trying to control the spinal curve degree by using forces from outside. (bracing) to intervene the spinal curve progression is highly recommended for patients with particular clinical characteristics. However, bracing is not always a present experience apart from function restriction. Clinical recommendation requires the patients to brace over 20 hours everyday, which means the patients have to be \"braced\" around the clock. Patients' perception on being \"braced\" all day, apart from discomforts under bracing, self-image and mental health after bracing are also important psycho-social factors which have yet to be addressed. Based on our clinical experience, 1-2% of AIS patients, undergoing bracing or not (i.e. at observation stage), require surgical intervention due to rapid spinal progression in a short period of time. By definition, surgery will be arranged for patients with major spinal curve ≥50. The use of health-related-quality-of-life (HRQoL) questionnaires allow clinical professionals to explore many different kinds of interests on patients, including the patient's feeling on his\u002Fher medical condition and satisfaction with provided care. Scoliosis Research Society (SRS) patient outcome tool has been a well-accepted HRQoL questionnaire to look for the perception of patients with spinal problems of their status. The SRS-22 questionnaire that has been well accepted as its trustworthy on the score results and SRS-22 is good to be used in patients under different conditions across the disease. This is very important to obtain and compare the scores over time in order to look for any consistent changes. Apart from AIS patients requiring bracing, surgical cases are also very important group of patients to monitor their quality of life before and after surgery, and every follow-up visit after surgery.",[153,154,155,34],"Scoliosis; Adolescence","Adolescent","Quality of Life",[157,158,159,160,161,162],"scoliosis","adolescent idiopathic scoliosis","bracing","surgery","quality of life","questionnaire","2025-02-10",{"date":165,"type":48},"2025-02-12",{"date":167,"type":48},"2019-07-01",{"date":169,"type":20},"2029-07",{"name":171,"class":55},"Chinese University of Hong Kong"]